Paramount Faces Political Scrutiny as Foreign Backing Sparks New National Security Review

The DOJ subpoenas are not a surprise. They confirm the regulatory probe is moving ahead, with the agency seeking details on studio output, content rights, and streaming competition. This is the expected next step in a process the market has already been pricing for months. The real question is whether this new information changes the risk calculus.

Paramount's Chief Legal Officer stated the company had been expecting authorities in many places to review the deal. That expectation is key. This isn't an unexpected shock that resets the entire narrative. It's the confirmation that the regulatory hurdles are real and active, which was already the consensus view.

The stock's reaction tells the deeper story. The shares have fallen over 34% in the last 20 days and are down 54% over 120 days. That kind of sustained decline suggests significant regulatory risk was already baked into the price. The subpoenas, while adding a new layer of scrutiny, are likely just the latest piece of news in a long, painful discounting process. The market's expectation gap has been closing for months.

So, is this a material new risk? Not really. It's more of a known risk being operationalized. The core deal risk-the possibility of a costly block-was already heavily priced in. The subpoenas simply formalize the investigation. For investors, the focus now shifts from whether regulation is a risk (it is) to whether the company's response and the DOJ's timeline will now create a new expectation gap.

Valuation vs. Reality: Is the Stock Truly Undervalued?

The stock trades at a deep discount, but that price is a direct reflection of a brutal reality check. Shares are hovering near their 52-week low of $8.62, down 34% year-to-date. This isn't a bargain based on fundamentals; it's the market's verdict on a merger that now looks far more expensive and risky than it did a year ago.

The core of the valuation puzzle is the massive capital required to fund the combined entity. Analyst Wolfe Research highlights a stark need for a $13 billion to $25 billion equity raise post-close. That figure underscores the sheer scale of the debt load Paramount is inheriting. The company's plan to become a vertically integrated media giant requires this enormous investment, but it also means a significant dilution of existing shareholders. The market is pricing in that future cost.

Against this backdrop, the potential $7 billion cost of deal failure is a tangible, near-term risk. This isn't a distant "what if." It's a concrete financial hit that Paramount has already committed to paying if the merger is blocked. The stock's steep decline suggests this risk is fully baked in. The expectation gap has been closed for months; the market is no longer guessing about the deal's fate, it's pricing the consequences.

So, is the stock undervalued? The numbers tell a mixed story. The enterprise value of $20.16 billion is less than the $110 billion deal value, but that gap reflects the market's severe skepticism. The valuation metrics-like a negative P/E and a price-to-sales ratio under 0.8-are typical of a company in distress. The real question for investors is whether the stock has fallen far enough to account for both the massive dilution required to close the deal and the $7 billion penalty if it fails. The current price suggests it has, but the path to resolution remains fraught.

Catalysts and Risks: The Path to April 23 and Beyond

The immediate test for Paramount Skydance is the Warner Bros Discovery shareholder vote scheduled for April 23. This procedural step is a key milestone that, if approved, would bring the deal closer to completion. However, it is not a final victory. The vote is a necessary but insufficient condition for closing, as the merger still faces intense scrutiny from U.S. and European regulators. The market's expectation gap here is narrow; the vote itself is not expected to be a major surprise, but its outcome will set the stage for the next, more consequential phase.

The primary catalyst for the stock's stabilization or reversal will be the resolution of the antitrust reviews. The DOJ has already signaled that fast-track approval is off the table, warning the merger will not receive a fast-track approval due to political factors. This is a critical reality check. It means the process will be prolonged and uncertain, likely extending into the second half of the year. The market has priced in a long, drawn-out regulatory battle, but any concrete sign of a path forward-or a major new hurdle-could quickly reset expectations.

A new vector of risk has emerged from Capitol Hill. US lawmakers are urging federal regulators to launch a full national security review focused on the foreign financial backing in the deal. This introduces a separate layer of political scrutiny that goes beyond traditional antitrust concerns. It centers on potential foreign influence over media assets, which could lead to delays, impose new conditions on the transaction, or even affect the ownership structure. This development adds a distinct and unpredictable risk that was not part of the initial regulatory calculus.

The bottom line is that the stock's deep discount reflects a market that has already priced in a high probability of a long, complex regulatory process. The April 23 vote is a step, but the real catalysts are the antitrust decisions and the potential for new political scrutiny. Any progress on those fronts could narrow the expectation gap and support a recovery. Conversely, further delays or new conditions would likely widen it, pressuring the stock further. For now, the path is clear: the market is waiting for the regulatory and political fog to lift.